StonvexLoading…
StonvexStonvexStonvexCore line items from ENTX's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $0.00 | $42.00K | $42.00K | $42.00K |
Operating Income | $-3.54M | $-11.53M | $-8.49M | $-5.23M |
Net Income | $-3.50M | $-11.44M | $-8.42M | $-5.22M |
EPS (Diluted) | $0.07 | $0.25 | $0.18 | $0.12 |
Total Assets | $13.13M | $15.99M | $17.41M | $19.67M |
Total Liabilities | $2.44M | $2.89M | $2.17M | $2.41M |
Cash & Equivalents | $4.14M | $7.11M | $8.57M | $10.86M |
Free Cash Flow OCF − CapEx | $-3.09M | $-7.48M | $-5.62M | $-3.07M |
Shares Outstanding | 46.62M | 46.18M | 45.66M | 45.45M |